MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. AMWL
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

American Well (AMWL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

American Well
NYSE•Healthcare•Health Information Services
$12.70+0.39(0.03%)Market open
Market Cap
$223.42M
P/S
1.0x
P/B
1.0x

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. It serves providers, payers, and the government, as well as the higher education sector. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

D

How this company scores

WeakMetricSide Score: 38/100

Grade capped at D — Interest coverage below 1× (-33.0x) — earnings cannot cover interest. Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (7/25).

Profitability17/25
Growth7/25
Balance Sheet & Red Flags7/25
Cash & Earnings Quality7/25
Strengths
Long cash runwayProfit converts from growthNet cash positionImproving margins
Grade capped at D
  • Interest coverage below 1× (-33.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.0x5y range 0.3x – 128.2x
P/S 1.0x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 1.0x5y range 0.3x – 36.3x
P/B 1.0x · below its 20-quarter median

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $223.42M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$218.53M
4Q
Q. Revenue
$52.05M
4Q
TTM EBITDA
$-48.94M
7Q
TTM Op. Income
$-81.46M
7Q
Q. Op. Income
$-9.56M
3Q
TTM Net Income
$-78.11M
7Q
Q. Net Income
$-9.93M
3Q
EPS
$-0.59
3Q
Shares Out.
$16.76M
6Q
$218.53M in TTM revenue declined 19.0% YoY, reaching $52.05M last quarter. TTM EBITDA of $-48.94M and TTM operating income of $-81.46M show growth is flowing through to the bottom line. However, net income is negative at $78.11M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 4 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
53.0%
6%
EBITDA Margin
-4.9%
3Q
Op. Margin
-18.4%
3Q
Net Margin
-19.1%
3Q
Op. margin of -18.4% is up 10.4% YoY — cost efficiency is improving. Net margin at -19.1% and gross margin of 53.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
1.0x
2Q
P/B Ratio
1.0x
2Q
P/S of 1.0x and P/B of 1.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$327.18M
2Q
Cash
$195.95M
11%
Long-Term Debt
N/A
Book Value
$221.22M
7Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$10.72M
3Q
TTM Free Cash Flow
$-26.41M
2Q
FCF Margin
-12.1%
2Q
FCF / Net Income
0.3
2Q
TTM FCF of $-26.41M on $10.72M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Revenue Decline

Watch

Revenue has softened, declining in 4 quarters. Watch for further erosion.

Cash Burn

Red Flag

The last 7 consecutive quarters had negative FCF — the company is burning cash and may need external funding.

Share Dilution

Red Flag

Shares outstanding increased 10.7% — significant dilution, likely from stock compensation or capital raises.